Navigation Links
ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
Date:1/5/2011

THOUSAND OAKS, Calif., Jan. 5, 2011 /PRNewswire/ -- ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a collaboration in which Cephalon Australia (a wholly owned subsidiary of Cephalon, Inc.) will apply ImmunGene's interferon payload technology to up to six of its new drug targets for cancers.

Under terms of the collaboration, Cephalon Australia will pay undisclosed fees including an up-front payment to ImmunGene for a four-year option to leverage ImmunGene's novel drug development technology in preclinical research on up to six of Cephalon Australia's drug candidates. Cephalon has the option to pay ImmunGene license fees for exclusivity on each of these candidates that it decides to move into clinical trials.

Cephalon Australia is responsible for research, clinical development, manufacturing and commercialization of products that result from the ImmunGene collaboration.  ImmunGene is eligible to receive considerable payments for research, clinical and regulatory milestones for each drug candidate in the collaboration that is commercialized, in addition to royalties on worldwide net sales of any resulting products.

Dr. Sanjay Khare, CEO of ImmunGene, said, "This collaboration is a validation of ImmunGene's novel antibody function enhancement technology that adds the power of cytokines to antibodies while reducing the systemic toxicity of the cytokines."  Dr. Raj Sachdev, ImmunGene's Chief Operating Officer, added, "We are pleased to have Cephalon Australia as a partner with its strong commitment to advancing this new class of protein therapeutics."

ImmunGene is leveraging promising science to tap the power of the immune system to develop therapeutic antibodies with increased efficacy and superior safety compared to existing therapies.

ImmunGene's breakthrough technology platform, available for non-exclusive licensing, offers pharma and biotech companies the possibility of utilizing its technology platform to fuse cytokines to antibodies that selectively target diseased cells and tissues while reducing the systemic toxicity of the cytokines. Using as little as 1/100 of the usual cancer therapeutic dose, products employing ImmunGene's technology promise safety with the power to kill tumor cells, limit blood supply and turn off genes that support tumor growth. Thus, ImmunGene offers the possibility of utilizing lower doses of their drug candidates for clinical efficacy, simplifying the manufacturing process, and lowering cost of goods.

About ImmunGene, Inc.

ImmunGene is a privately-held, drug discovery and development company, tapping the power of the immune system to develop the next generation of antibody-based therapeutics to treat cancer, autoimmune and infectious diseases. Our technology platform, available for non-exclusive licensing, offers pharma and biotech companies the possibility of utilizing lower doses of their drug candidates for enhanced clinical efficacy, simplifying the manufacturing process, and lowering cost of goods. Our three novel pipeline candidates are antibody-cytokine fusions that have demonstrated targeted efficacy superior to existing therapies in vitro and in vivo testing. For more information please visit www.immungene.com.

About Cephalon, Inc.

Cephalon is a global pharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1,000 and a member of the S&P 500 index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.  More information on Cephalon and its products are available at http://www.cephalon.com.

Cephalon Australia is a wholly owned subsidiary of Cephalon, Inc.

This press release contains certain forward-looking statements relating to our business. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs. There can be no assurance that any product in ImmunGene's pipeline or technology platform will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.


'/>"/>
SOURCE ImmunGene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmunGenes Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):